Lineage Cell Therapeutics, Inc. (LCTX) — SC 13D/A Filings
All SC 13D/A filings from Lineage Cell Therapeutics, Inc.. Browse 2 SC 13D/A reports with AI-powered summaries and risk analysis.
SC 13D/A Filings (2)
-
Broadwood Partners Amends Lineage Cell Therapeutics Stake
— Nov 21, 2024 Risk: medium
Broadwood Partners, L.P. filed an amendment (No. 27) to its Schedule 13D on November 21, 2024, regarding its holdings in Lineage Cell Therapeutics, Inc. The fil -
Broadwood Partners Cuts Lineage Cell Therapeutics Stake to 24.9%
— Feb 8, 2024 Risk: low
Broadwood Partners, L.P. filed an Amendment No. 26 to their Schedule 13D, indicating a change in their beneficial ownership of Lineage Cell Therapeutics, Inc. c
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX